Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

Transforming growth factor-β (TGFβ) is an important driver of tumor growth via intrinsic and extrinsic mechanisms, and is therefore an attractive target for developing cancer therapeutics. Using preclinical models, we characterized the anti-tumor activity of a small molecule inhibitor of TGFβ recept...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Yingling, Jonathan M., McMillen, William T., Yan, Lei, Huang, Huocong, Sawyer, J. Scott, Graff, Jeremy, Clawson, David K., Britt, Karen S., Anderson, Bryan D., Beight, Douglas W., Desaiah, Durisala, Lahn, Michael M., Benhadji, Karim A., Lallena, Maria J., Holmgaard, Rikke B., Xu, Xiaohong, Zhang, Faming, Manro, Jason R., Iversen, Philip W., Iyer, Chandrasekar V., Brekken, Rolf A., Kalos, Michael D., Driscoll, Kyla E.
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2017
Materias:
Priority Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5805504/
https://ncbi.nlm.nih.gov/pubmed/29467918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23795
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares